J. Blatter, Phase II study of gemcitabine in patients with advanced pancreatic cancer, Br. J. Cancer, vol.73, pp.101-105, 1996.

M. Quisumbing, G. Shapiro, R. Witte, and J. H. Schiller, Phase II study of second-line gemcitabine in sensitive or refractory small cell lung cancer, Lung Cancer, vol.42, pp.97-102, 2003.

A. Denise and Y. , Gemcitabine plus paclitaxel in breast cancer, Semin. Oncol, vol.32, issue.4, pp.14-21, 2005.

R. F. Ozols, Gemcitabine and Carboplatin in Second-Line Ovarian Cancer, Seminars in Oncology, vol.32, issue.4, pp.4-8, 2005.
DOI : 10.1053/j.seminoncol.2005.06.023

D. R. Rauchwerger, P. S. Firby, D. W. Hedley, and M. J. Moore, Equilibrativesensitive nucleoside transporter and its role in gemcitabine sensitivity, Cancer Res, vol.60, pp.6075-6079, 2000.

J. J. Farrell, H. Elsaleh, M. Garcia, R. Lai, A. Ammar et al., Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer, Gastroenterology, vol.136, issue.1, pp.187-195, 2009.
DOI : 10.1053/j.gastro.2008.09.067

M. S. Duxbury, H. Ito, M. J. Zinner, S. W. Ashley, and E. E. Whang, RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine, Oncogene, vol.23, issue.8, pp.1539-1548, 2004.
DOI : 10.1038/sj.onc.1207272

M. Zacchigna, F. Cateni, S. Drioli, and G. M. Bonora, Multimeric, Multifunctional Derivatives of Poly(ethylene glycol), Polymers, vol.3, issue.4, pp.1076-1090, 2011.
DOI : 10.3390/polym3031076

B. B. Lundberg, V. Risovic, M. Ramaswamy, and K. M. Wasan, A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration, Journal of Controlled Release, vol.86, issue.1, pp.93-100, 2003.
DOI : 10.1016/S0168-3659(02)00323-1

M. L. Sandvold, H. R. Hendriks, and G. J. Peters, Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines, Biochem. Pharmacol, vol.67, pp.503-511, 2004.

P. Reichard, Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment, Proc. Natl. Acad. Sci. U.S.A, vol.91, pp.8403-8407, 1994.

A. Stathis and M. J. Moore, Advanced pancreatic carcinoma: current treatment and future challenges, Nature Reviews Clinical Oncology, vol.61, issue.3, pp.163-172, 2010.
DOI : 10.1038/nrclinonc.2009.236

E. Lilly and C. Gemzar, Gemcitabine HCL) for injection, 2005.

J. M. Reid, W. Qu, S. L. Safgren, M. M. Ames, M. D. Krailo et al., Phase I Trial and Pharmacokinetics of Gemcitabine in Children With Advanced Solid Tumors, Journal of Clinical Oncology, vol.22, issue.12, pp.2445-2451, 2004.
DOI : 10.1200/JCO.2004.10.142

J. L. Abbruzzese, R. Grunewald, E. A. Weeks, D. Gravel, T. Adams et al., A phase I clinical, plasma, and cellular pharmacology study of gemcitabine., Journal of Clinical Oncology, vol.9, issue.3, pp.491-498, 1991.
DOI : 10.1200/JCO.1991.9.3.491

D. A. Griffith and S. M. Jarvis, Nucleoside and nucleobase transport systems of mammalian cells, Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes, vol.1286, issue.3, pp.153-181, 1996.
DOI : 10.1016/S0304-4157(96)00008-1

R. J. Paproski, A. M. Ng, S. Y. Yao, K. Graham, J. D. Young et al., The Role of Human Nucleoside Transporters in Uptake of 3'-Deoxy-3'-fluorothymidine, Molecular Pharmacology, vol.74, issue.5, pp.1372-1380, 2008.
DOI : 10.1124/mol.108.048900

H. Ueno, K. Kiyosawa, and N. Kaniwa, Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?, British Journal of Cancer, vol.24, issue.2, pp.145-151, 2007.
DOI : 10.1097/00008571-200301000-00005

L. S. Hodge, M. E. Taub, and T. S. Tracy, Effect of its deaminated metabolite, 2???,2???-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells, Biochemical Pharmacology, vol.81, issue.7, pp.950-956, 2011.
DOI : 10.1016/j.bcp.2011.01.016

Y. Fujii, I. Endo, S. Togo, P. V. Danenberg, and H. Shimada, Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells, Oncol. Rep, vol.17, pp.1201-1205, 2007.

F. Mosca and R. Danesi, Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine, Cancer Res, vol.66, pp.3928-3935, 2006.

W. Plunkett, P. Huang, and V. Gandhi, Preclinical characteristics of gemcitabine, Anti-Cancer Drugs, vol.6, issue.Supplement 6, pp.7-13, 1995.
DOI : 10.1097/00001813-199512006-00002

M. Barton-burke, Gemcitabine: a pharmacologic and clinical overview. Cancer Nurs, pp.176-183, 1999.

W. Plunkett, Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation, Cancer Res, vol.52, pp.533-539, 1992.

R. S. Jansen, H. Rosing, J. H. Schellens, and J. H. Beijnen, Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?, Fundamental & Clinical Pharmacology, vol.7, issue.Pt B, pp.172-185, 2011.
DOI : 10.1111/j.1472-8206.2010.00823.x

A. M. Bergman, H. M. Pinedo, and G. J. Peters, Determinants of resistance to 2???,2???-difluorodeoxycytidine (gemcitabine), Drug Resistance Updates, vol.5, issue.1, pp.19-33, 2002.
DOI : 10.1016/S1368-7646(02)00002-X

S. Komori, S. Osada, R. Mori, S. Matsui, Y. Sanada et al., Contribution of Thymidylate Synthase to Gemcitabine Therapy for Advanced Pancreatic Cancer, Pancreas, vol.39, issue.8, pp.1284-1292, 2010.
DOI : 10.1097/MPA.0b013e3181dec17d

V. W. Ruiz-van-haperen, G. Veerman, J. B. Vermorken, and G. J. Peters, 2???,2???-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines, Biochemical Pharmacology, vol.46, issue.4, pp.762-766, 1993.
DOI : 10.1016/0006-2952(93)90566-F

M. L. Clarke, J. R. Mackey, S. A. Baldwin, J. D. Young, and C. Cass, The Role of Membrane Transporters in Cellular Resistance to Anticancer Nucleoside Drugs, Cancer Treat. Res, vol.112, pp.27-47, 2002.
DOI : 10.1007/978-1-4615-1173-1_2

R. Maréchal, J. R. Mackey, R. Lai, P. Demetter, M. Peeters et al., Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma, Clinical Cancer Research, vol.15, issue.8, pp.2913-2919, 2009.
DOI : 10.1158/1078-0432.CCR-08-2080

A. Russo, J. Mackey, A. Falcone, and G. Tonini, Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC), Curr. Cancer Drug Targets, vol.11, pp.123-129, 2011.

A. Klein, D. Laheru, and C. A. Iacobuzio-donahue, Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival, Clin. Cancer Res, vol.12, pp.2492-2497, 2006.

B. S. Zhou, P. Tsai, R. Ker, J. Tsai, R. Ho et al., Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential, Clinical and Experimental Metastasis, vol.16, issue.1, pp.43-49, 1998.
DOI : 10.1023/A:1006559901771

J. Zhou, P. Oliveira, X. Li, Z. Chen, and G. Bepler, Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines, Journal of Nucleic Acids, vol.51, issue.22, p.597098, 2010.
DOI : 10.1158/0008-5472.CAN-05-4462

H. Fujita, K. Ohuchida, K. Mizumoto, S. Itaba, T. Ito et al., Gene Expression Levels as Predictive Markers of Outcome in Pancreatic Cancer after Gemcitabine-Based Adjuvant Chemotherapy, Neoplasia, vol.12, issue.10, pp.807-817, 2010.
DOI : 10.1593/neo.10458

C. Tolis, G. Peters, C. G. Ferreira, H. M. Pinedo, and G. Giaccone, Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines, European Journal of Cancer, vol.35, issue.5, pp.796-807, 1999.
DOI : 10.1016/S0959-8049(98)00425-0

P. Dasgupta, A. Keen, J. C. Yeo, C. J. Gorospe, M. Brody et al., The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR-upregulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase, Cancer Res, vol.69, pp.4567-4572, 2009.

H. Rui, G. Gonye, E. P. Kennedy, C. J. Yeo, J. R. Brody et al., HuR status is a powerful marker for prognosis and response to gemcitabine-based chemotherapy for resected pancreatic ductal adenocarcinoma patients, Ann. Surg, vol.252, pp.499-505, 2010.

A. M. Storniolo, S. R. Allerheiligen, and H. L. Pearce, Preclinical, pharmacologic, and phase I studies of gemcitabine, Semin. Oncol, vol.24, issue.2, pp.7-9, 1997.

A. Mero, C. Clementi, F. M. Veronese, and G. Pasut, Covalent Conjugation of Poly(Ethylene Glycol) to Proteins and Peptides: Strategies and Methods, Methods Mol. Biol, vol.751, pp.95-129, 2011.
DOI : 10.1007/978-1-61779-151-2_8

G. Pasut and F. M. Veronese, State of the art in PEGylation: The great versatility achieved after forty years of research, Journal of Controlled Release, vol.161, issue.2, pp.461-472, 2012.
DOI : 10.1016/j.jconrel.2011.10.037

G. Pasut and F. M. Veronese, PEG conjugates in clinical development or use as anticancer agents: An overview, Advanced Drug Delivery Reviews, vol.61, issue.13, pp.61-1177, 2009.
DOI : 10.1016/j.addr.2009.02.010

R. M. Sawant, Polyethylene glycol (peg) as a key component of long-circulating delivery systems for therapy and imaging, Pharm. Sci. Dissert, pp.1-107, 2008.

P. Caliceti and F. M. Veronese, Pharmacokinetic and biodistribution properties of poly(ethylene glycol)???protein conjugates, Advanced Drug Delivery Reviews, vol.55, issue.10, pp.1261-1277, 2003.
DOI : 10.1016/S0169-409X(03)00108-X

H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori, Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review, Journal of Controlled Release, vol.65, issue.1-2, pp.271-284, 2000.
DOI : 10.1016/S0168-3659(99)00248-5

J. Szebeni, Complement activation-related pseudoallergy: A new class of drug-induced acute immune toxicity, Toxicology, vol.216, issue.2-3, pp.106-121, 2005.
DOI : 10.1016/j.tox.2005.07.023

J. Liu, P. Zahedi, F. Zeng, and C. Allen, Nano-Sized Assemblies of a PEG-Docetaxel Conjugate as a Formulation Strategy for Docetaxel, Journal of Pharmaceutical Sciences, vol.97, issue.8, pp.3274-3290, 2008.
DOI : 10.1002/jps.21245

C. Li, D. Yu, T. Inoue, D. J. Yang, L. Milas et al., Synthesis and evaluation of water-soluble polyethylene glycol-paclitaxel conjugate as a paclitaxel prodrug, Anti-Cancer Drugs, vol.7, issue.6, pp.642-648, 1996.
DOI : 10.1097/00001813-199608000-00004

M. Vandana and S. K. Sahoo, Long circulation and cytotoxicity of PEGylated gemcitabine and its potential for the treatment of pancreatic cancer, Biomaterials, vol.31, issue.35, pp.9340-9356, 2010.
DOI : 10.1016/j.biomaterials.2010.08.010

T. Cheng, Endocytosis of PEGylated Agents Enhances Cancer Imaging and Anticancer Efficacy, Molecular Cancer Therapeutics, vol.9, issue.6, pp.1903-1912
DOI : 10.1158/1535-7163.MCT-09-0899

L. M. Bareford and P. W. Swaan, Endocytic mechanisms for targeted drug delivery???, Advanced Drug Delivery Reviews, vol.59, issue.8
DOI : 10.1016/j.addr.2007.06.008

G. Pasut, F. Canal, L. Via, S. Arpicco, F. M. Veronese et al., Antitumoral activity of PEG???gemcitabine prodrugs targeted by folic acid, Journal of Controlled Release, vol.127, issue.3, pp.239-248, 2008.
DOI : 10.1016/j.jconrel.2008.02.002

M. Goode, E. L. Kamen, B. A. Low, P. S. Knutson, K. L. Iwakiri et al., Functional folate receptor alpha is elevated in the blood of ovarian cancer patients Expression status of folate receptor alpha is significantly correlated with prognosis in non-smallcell lung cancers, PLoS ONE Ann. Surg. Oncol, vol.4, issue.15, pp.6292-55, 2008.

D. Hillman, A. L. Oberg, and P. S. Low, Folate receptor overexpression is associated with poor outcome in breast cancer, Int. J. Cancer, vol.121, pp.938-942, 2007.

H. Shmeeda, Y. Amitay, J. Gorin, D. Tzemach, L. Mak et al., Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells, Journal of Controlled Release, vol.146, issue.1, pp.76-83, 2010.
DOI : 10.1016/j.jconrel.2010.04.028

S. Yang, F. Lin, K. Tsai, M. Wei, H. Tsai et al., Folic Acid-Conjugated Chitosan Nanoparticles Enhanced Protoporphyrin IX Accumulation in Colorectal Cancer Cells, Bioconjugate Chemistry, vol.21, issue.4, pp.679-689, 2010.
DOI : 10.1021/bc9004798

P. Dubois, M. Saboungi, and I. Chourpa, Magnetic nanocarriers of doxorubicin coated with poly(ethylene glycol) and folic acid: relation between coating structure, surface properties, colloidal stability and cancer cell targeting, Langmuir, vol.28, pp.1496-1505, 2011.
URL : https://hal.archives-ouvertes.fr/hal-01387921

O. Schiavon, G. Pasut, S. Moro, P. Orsolini, A. Guiotto et al., PEG???Ara-C conjugates for controlled release, European Journal of Medicinal Chemistry, vol.39, issue.2, pp.123-133, 2004.
DOI : 10.1016/j.ejmech.2003.10.005

E. Dauty, J. Remy, G. Zuber, and J. Behr, Intracellular Delivery of Nanometric DNA Particles via the Folate Receptor, Bioconjugate Chemistry, vol.13, issue.4, pp.831-839, 2002.
DOI : 10.1021/bc0255182

J. M. Harris and R. B. Chess, Effect of pegylation on pharmaceuticals, Nature Reviews Drug Discovery, vol.18, issue.3, pp.214-221, 2003.
DOI : 10.1038/nrd1033

J. J. Starling, G. A. Stephenson, R. K. Vaid, D. Zhang, and J. R. Mccarthy, Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine, J. Med. Chem, vol.52, pp.6958-6961, 2009.

S. L. Koolen, P. O. Witteveen, R. S. Jansen, M. H. Langenberg, R. H. Kronemeijer et al., Phase I Study of Oral Gemcitabine Prodrug (LY2334737) Alone and in Combination with Erlotinib in Patients with Advanced Solid Tumors, Clinical Cancer Research, vol.17, issue.18, pp.6071-6082, 2011.
DOI : 10.1158/1078-0432.CCR-11-0353

Z. Huang, Y. Lin, and J. Fang, Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology, Molecules, vol.14, issue.1, pp.540-554, 2009.
DOI : 10.3390/molecules14010540

G. S. Kelly, Squalene and its potential clinical uses, Altern. Med. Rev, vol.4, issue.66, pp.29-36, 1999.

H. L. Newmark, Squalene, Olive Oil, and Cancer Risk: Review and Hypothesis, Annals of the New York Academy of Sciences, vol.84, issue.4, pp.1101-1103, 1997.
DOI : 10.1007/BF01990031

V. Marsaud, J. Renoir, and L. Cattel, Squalenoyl nanomedicines as potential therapeutics, Nano Lett, vol.6, pp.2544-2548, 2006.

D. Desmaële, R. Gref, and P. Couvreur, Squalenoylation: A generic platform for nanoparticular drug delivery, Journal of Controlled Release, vol.161, issue.2, pp.609-618, 2012.
DOI : 10.1016/j.jconrel.2011.07.038

L. P. Jordheim, E. Cros, M. Gouy, C. M. Galmarini, S. Peyrottes et al., Characterization of a Gemcitabine-Resistant Murine Leukemic Cell Line: Reversion of In vitro Resistance by a Mononucleotide Prodrug, Clinical Cancer Research, vol.10, issue.16, pp.5614-5621, 2004.
DOI : 10.1158/1078-0432.CCR-04-0506

N. Lee, J. R. Mackey, J. D. Young, J. Jolivet, R. G. Lafrenière et al., Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines, Cancer Res, pp.61-7217, 2001.

P. Couvreur, A new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia types, J. Control. Release, vol.124, pp.20-27, 2007.

S. Réjiba, L. H. Reddy, C. Bigand, C. Parmentier, P. Couvreur et al., Squalenoyl gemcitabine nanomedicine overcomes the low efficacy of gemcitabine therapy in pancreatic cancer, Nanomedicine: Nanotechnology, Biology and Medicine, vol.7, issue.6, pp.841-849, 2011.
DOI : 10.1016/j.nano.2011.02.012

P. Couvreur, Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation, Nanoscale, vol.2, pp.1521-1526, 2010.

F. Dosio, R. Gref, and P. Couvreur, Squalene based nanocomposites: a new platform for the design of multifunctional pharmaceutical theragnostics, ACS Nano, vol.5, pp.1513-1521, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00589109

A. Sarasin, H. Bénech, S. Lepêtre-mouelhi, D. Desmaële, and P. Couvreur, Transmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: An original drug delivery pathway, J. Control. Release, vol.147, pp.163-170, 2010.

I. Podgorski and B. Sloane, Cathepsin B and its role(s) in cancer progression, Biochemical Society Symposium, vol.70, pp.263-276, 2003.
DOI : 10.1042/bss0700263

Z. Yang and J. L. Cox, Cathepsin L increases invasion and migration of B16 melanoma, Cancer Cell International, vol.7, issue.1, 2007.
DOI : 10.1186/1475-2867-7-8

C. Celia, D. Cosco, D. Paolino, and M. Fresta, antitumor activity, Expert Opinion on Drug Delivery, vol.30, issue.2, pp.1609-1629, 2011.
DOI : 10.1111/j.1464-410X.2010.09496.x

F. Dosio, L. H. Reddy, A. Ferrero, B. Stella, L. Cattel et al., Novel Nanoassemblies Composed of Squalenoyl???Paclitaxel Derivatives: Synthesis, Characterization, and Biological Evaluation, Bioconjugate Chemistry, vol.21, issue.7, pp.1349-1361, 2011.
DOI : 10.1021/bc100154g

L. A. Taylor, C. Unger, and U. Massing, Anti-metastatic effects of liposomal gemcitabine in a human orthotopic LNCaP prostate cancer xenograft model, Clin. Exp. Metastasis, vol.26, pp.981-992, 2009.

S. Aggarwal, S. Yadav, and S. Gupta, EGFR Targeted PLGA Nanoparticles Using Gemcitabine for Treatment of Pancreatic Cancer, Journal of Biomedical Nanotechnology, vol.7, issue.1, pp.137-138, 2011.
DOI : 10.1166/jbn.2011.1238

F. Yang, C. Jin, D. Yang, Y. Jiang, J. Li et al., Magnetic functionalised carbon nanotubes as drug vehicles for cancer lymph node metastasis treatment, European Journal of Cancer, vol.47, issue.12, pp.1873-1882, 2011.
DOI : 10.1016/j.ejca.2011.03.018

C. A. Ventura, C. Cannavà, R. Stancanelli, D. Paolino, D. Cosco et al., Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation, Biomedical Microdevices, vol.356, issue.5, pp.799-807, 2011.
DOI : 10.1007/s10544-011-9550-6

P. Couvreur, Encapsulation of gemcitabine lipophilic derivatives into polycyanoacrylate nanospheres and nanocapsules, Int. J. Pharm, vol.344, pp.71-77, 2007.

G. Arya, M. Vandana, S. Acharya, and S. K. Sahoo, Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy, Nanomedicine: Nanotechnology, Biology and Medicine, vol.7, issue.6, pp.859-870, 2011.
DOI : 10.1016/j.nano.2011.03.009

L. Cattel, M. Ceruti, and F. Dosio, From Conventional to Stealth Liposomes: a New Frontier in Cancer Chemotherapy, Journal of Chemotherapy, vol.2000, issue.sup4, pp.237-249, 2003.
DOI : 10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H

P. Milla and F. Dosio, PEGylation of Proteins and Liposomes: a Powerful and Flexible Strategy to Improve the Drug Delivery, Current Drug Metabolism, vol.13, issue.1, pp.105-109, 2012.
DOI : 10.2174/138920012798356934

M. L. Immordino, P. Brusa, F. Rocco, S. Arpicco, and M. Ceruti, Preparation, characterization, cytotoxicity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs, Journal of Controlled Release, vol.100, issue.3, pp.331-346, 2004.
DOI : 10.1016/j.jconrel.2004.09.001

Y. Tokunaga, T. Iwasa, J. Fujisaki, S. Sawai, and A. Kagayama, Liposomal sustained-release delivery systems for intravenous injection. IV. Antitumor activity of newly synthesized lipophilic 1-.BETA.-D-arabinofuranosylcytosine prodrug-bearing liposomes., CHEMICAL & PHARMACEUTICAL BULLETIN, vol.36, issue.9, pp.3574-3583, 1988.
DOI : 10.1248/cpb.36.3574

P. Brusa, M. L. Immordino, F. Rocco, and L. Cattel, Antitumor activity and pharmacokinetics of liposomes containing lipophilic gemcitabine prodrugs, Anticancer Res, vol.27, pp.195-199, 2007.

B. R. Sloat, M. A. Sandoval, D. Li, W. Chung, D. S. Lansakara-p et al., In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles, International Journal of Pharmaceutics, vol.409, issue.1-2, pp.278-288, 2011.
DOI : 10.1016/j.ijpharm.2011.02.037

W. Chung, M. A. Sandoval, B. R. Sloat, D. S. Lansakara-p, and Z. Cui, Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1, Journal of Controlled Release, vol.157, issue.1, pp.132-140, 2012.
DOI : 10.1016/j.jconrel.2011.08.004

K. Kiguchi, J. Digiovanni, and Z. Cui, EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity, J. Control. Release, vol.157, pp.287-296, 2012.

E. Batrakova, Sensitizing of gemcitabine-resistant human leukemia cells by stearoyl gemcitabine nanoparticles. Nanomedecien (Lond, pp.1491-1492, 2011.

R. I. Nicholson, J. M. Gee, and M. E. Harper, EGFR and cancer prognosis, European Journal of Cancer, vol.37, pp.9-15, 2001.
DOI : 10.1016/S0959-8049(01)00231-3

T. Yokoyama, J. Tam, S. Kuroda, A. W. Scott, J. Aaron et al., EGFR-Targeted Hybrid Plasmonic Magnetic Nanoparticles Synergistically Induce Autophagy and Apoptosis in Non-Small Cell Lung Cancer Cells, PLoS ONE, vol.4, issue.11, p.25507, 2011.
DOI : 10.1371/journal.pone.0025507.s005

J. Gao, Y. Yu, Y. Zhang, J. Song, H. Chen et al., EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma, Biomaterials, vol.33, issue.1, pp.270-282, 2012.
DOI : 10.1016/j.biomaterials.2011.09.035

R. Liu, J. M. Desimone, and R. J. Mumper, In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain, J. Control. Release, vol.158, pp.63-71, 2011.

A. D. Adema, I. V. Bijnsdorp, M. L. Sandvold, H. M. Verheul, and G. J. Peters, Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer, Current Medicinal Chemistry, vol.16, issue.35, pp.4632-4643, 2009.
DOI : 10.2174/092986709789878229

K. Breistøl, J. Balzarini, M. L. Sandvold, F. Myhren, M. Martinsen et al., Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models, Cancer Res, vol.59, pp.2944-2949, 1999.

S. Dueland, S. Aamdal, M. J. Lind, H. Thomas, M. L. Sandvold et al., Intravenous administration of CP-4055 (ELACYT???) in patients with solid tumours. A phase I study, Acta Oncologica, vol.28, issue.1, pp.137-145, 2009.
DOI : 10.1007/BF00321053

S. Pignata, F. Amant, G. Scambia, R. Sorio, E. Breda et al., A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy, Cancer Chemotherapy and Pharmacology, vol.92, issue.Suppl 1, pp.1347-1353, 2011.
DOI : 10.1007/s00280-011-1735-4

F. Myhren, M. L. Sandvold, and G. J. Peters, Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126, Invest. New Drugs, 2011.

C. M. Galmarini, F. Myhren, and M. L. Sandvold, CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines, British Journal of Haematology, vol.253, issue.2, pp.273-275, 2009.
DOI : 10.1111/j.1365-2141.2008.07467.x

M. L. Sandvold, C. Galmarini, F. Myhren, and G. Peters, The Activity of the Lipophilic Nucleoside Derivatives Elacytarabine and CP-4126 in a Panel of Tumor Cell Lines Resistant to Nucleoside Analogues, Nucleosides, Nucleotides and Nucleic Acids, vol.28, issue.4-6, pp.386-393, 2010.
DOI : 10.1200/JCO.2008.20.1111

V. Leblond, P. Diot, D. Grimbert, J. Racineux, and E. Lemarié, Safety of pulmonary administration of gemcitabine in rats, J. Aerosol Med, vol.18, pp.198-206, 2005.

A. D. Adema, A. C. Laan, F. Myhren, I. Fichtner, H. M. Verheul et al., Cell cycle effects of fatty acid derivatives of cytarabine, CP-4055, and of gemcitabine, CP-4126, as basis for the interaction with oxaliplatin and docetaxel, Int. J. Oncol, vol.36, issue.112, pp.285-294, 2010.

S. M. Ali, A. R. Khan, M. U. Ahmad, P. Chen, and S. Sheikh, Ahmad, I. Synthesis and biological evaluation of gemcitabine-lipid conjugate (NEO6002)

T. Sakamoto, T. Inoue, Y. Otomo, N. Yokomori, M. Ohno et al., Deficiency of Cardiolipin Synthase Causes Abnormal Mitochondrial Function and Morphology in Germ Cells of Caenorhabditis elegans, Journal of Biological Chemistry, vol.287, issue.7, pp.4590-4601, 2012.
DOI : 10.1074/jbc.M111.314823

I. Ahmad, A novel gemcitabine-cardiolipin conjugate induced cytotoxicity in cancer cells through an equilibrative nucleoside transporter-independent pathway. AACR Meeting Abstracts, 2005.

I. Ahmad, In-vitro and in-vivo anti-cancer activity of a novel gemcitabine-cardiolipin conjugate, Anticancer Drugs, vol.17, pp.53-61, 2006.

C. M. Galmarini, G. Warren, M. T. Senanayake, and S. V. Vinogradov, Efficient overcoming of drug resistance to anticancer nucleoside analogs by nanodelivery of active phosphorylated drugs, International Journal of Pharmaceutics, vol.395, issue.1-2, pp.281-289, 2010.
DOI : 10.1016/j.ijpharm.2010.05.028

D. Clercq, E. Imbach, J. L. Périgaud, C. Gosselin, and G. , Prodrugs of Ara-CMP and Ara-AMP with a S-acyl-2-thioethyl (SATE) biolabile phosphate protecting group: synthesis and biological evaluation, Nucleosides Nucleotides, vol.18, pp.971-972, 1999.

S. C. Tobias and R. Borch, Synthesis and Biological Studies of Novel Nucleoside Phosphoramidate Prodrugs, Journal of Medicinal Chemistry, vol.44, issue.25, pp.4475-4480, 2001.
DOI : 10.1021/jm010337r

C. Perigaud, S. Peyrottes, and C. Dumontet, Gemcitabine phosphoester prodrugs as anticancer agents, 2009.

J. Balzarini, The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5- fluoro-2?-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymes, Biochem. Pharmacol, vol.82, pp.441-452, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00721644

B. Ganguly, A. Kolykhalov, J. Wang, J. Muhammad, J. M. Patti et al., Design, synthesis and evaluation of a novel double pro-drug: INX-08189. A new clinical candidate for hepatitis C virus, Bioorg. Med. Chem. Lett, vol.20, pp.4850-4854, 2010.

J. Muhammad, N. Raja, C. R. Walters, J. Wang, K. Williams et al., INX-08189, a phosphoramidate prodrug of 6-O-methyl-2?-C-methyl guanosine, is a potent inhibitor of hepatitis C virus replication with excellent pharmacokinetic and pharmacodynamic properties

S. C. Tobias and R. Borch, Synthesis and Biological Evaluation of a Cytarabine Phosphoramidate Prodrug, Molecular Pharmaceutics, vol.1, issue.2, pp.112-116, 2004.
DOI : 10.1021/mp034019v

C. Mcguigan, Phosphoramidates of 2?-?-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism, Bioorg. Med. Chem, vol.18, pp.2439-2446, 2010.

W. Wu, J. Sigmond, G. J. Peters, and R. F. Borch, Synthesis and Biological Activity of a Gemcitabine Phosphoramidate Prodrug, Journal of Medicinal Chemistry, vol.50, issue.15, pp.3743-3746, 2007.
DOI : 10.1021/jm070269u

R. Nelson, F. A. Dorr, C. D. Stephens, and D. D. Von-hoff, Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial, J. Clin. Oncol, vol.15, pp.2403-2413, 1997.